Oncolytic Virus Therapies Market Size was approximately USD 122 Million in 2021

According to DelveInsight, Oncolytic Virus Therapies Market Size was approximately USD 122 million which is expected to rise during the study period (2019–2032) and is estimated to grow during the study period of 2019-2032. Oncolytic Virus Therapies have proven to be a powerful anticancer molecule, being able to be used for cancer diagnosis as well as treatment. Their multifunctional characteristics indicate good application prospects as cancer therapeutics, especially in combination with other therapies, such as radiotherapy, chemotherapy, and immunotherapy. Currently, only two oncolytic virus therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US and Europe in 2015, and DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) approved in Japan in 2021.

For More Information related to the Oncolytic Virus Therapies Market Research Report @ https://www.delveinsight.com/report-s...

#oncolyticviruscancer #oncolyticviruscancermarket #oncolyticviruscancermarketsize #oncolyticviruscancermarketshare
#oncolyticviruscancermarkettrends #oncolyticviruscancermarketinsight
#oncolyticviruscancermarketforecast #oncolyticviruscancermarketreport
#oncolyticviruscancermarketresearch #oncolyticviruscancersymptoms #oncolyticviruscancermarketresearchreport #oncolyticviruscancercompanies #oncolyticviruscancerdiagnosis

Follow us for regular updates-

LinkedIn-   / delveinsight-business-research-llp  

Twitter-   / delve_insight  

Facebook-   / delveinsightindia  

About DelveInsight
DelveInsight is a business consulting and market research firm that specialises in offering business solutions for the healthcare industry as well as essential advisory services in the fields of R&D, strategy formulation, operations, competitive intelligence, competitive landscaping, and mergers and acquisitions.

Email us at: [email protected]